Andecaliximab
drugOn this page
Also known as GS-5745GS5745
Summary
Andecaliximab (CHEMBL3833374) is a phase-3 clinical-stage antibody targeting MMP9; indicated across 6 conditions including gastric adenocarcinoma and ulcerative colitis.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Antibody
- Targets: 1 (MMP9)
- Indications: 6 conditions
- Clinical trials: 13
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL3833374 |
| Name | Andecaliximab |
| Type | Antibody |
| Max phase | 3 |
Also known as: Andecaliximab, GS-5745, GS5745, ANDECALIXIMAB
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| MMP9 | MMP9 | Binding | 9.66 | 0.1% | P14780 |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
Aggregated over 1 target gene(s): MMP9.
Top Reactome pathways
24 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Developmental Biology | 1 | MMP9 |
| Cytokine Signaling in Immune system | 1 | MMP9 |
| Signaling by SCF-KIT | 1 | MMP9 |
| Collagen degradation | 1 | MMP9 |
| Degradation of the extracellular matrix | 1 | MMP9 |
| Extracellular matrix organization | 1 | MMP9 |
| Collagen formation | 1 | MMP9 |
| Activation of Matrix Metalloproteinases | 1 | MMP9 |
| Signal Transduction | 1 | MMP9 |
| Innate Immune System | 1 | MMP9 |
| Immune System | 1 | MMP9 |
| Assembly of collagen fibrils and other multimeric structures | 1 | MMP9 |
| EPH-Ephrin signaling | 1 | MMP9 |
| EPH-ephrin mediated repulsion of cells | 1 | MMP9 |
| Axon guidance | 1 | MMP9 |
| Signaling by Interleukins | 1 | MMP9 |
| Interleukin-4 and Interleukin-13 signaling | 1 | MMP9 |
| Neutrophil degranulation | 1 | MMP9 |
| ESR-mediated signaling | 1 | MMP9 |
| Signaling by Nuclear Receptors | 1 | MMP9 |
| Signaling by Receptor Tyrosine Kinases | 1 | MMP9 |
| Extra-nuclear estrogen signaling | 1 | MMP9 |
| Nervous system development | 1 | MMP9 |
| Dengue Virus-Host Interactions | 1 | MMP9 |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| skeletal system development | 1 |
| positive regulation of protein phosphorylation | 1 |
| proteolysis | 1 |
| apoptotic process | 1 |
| embryo implantation | 1 |
| cell migration | 1 |
| extracellular matrix disassembly | 1 |
| extracellular matrix organization | 1 |
| macrophage differentiation | 1 |
| collagen catabolic process | 1 |
| endodermal cell differentiation | 1 |
| positive regulation of apoptotic process | 1 |
| negative regulation of apoptotic process | 1 |
| positive regulation of DNA binding | 1 |
| positive regulation of epidermal growth factor receptor signaling pathway | 1 |
Indications & clinical
Indications
6 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| gastric adenocarcinoma | 3 | MONDO:0005036 | EFO:0000503 |
| ulcerative colitis | 2 | MONDO:0005101 | EFO:0000729 |
| Crohn disease | 2 | MONDO:0005011 | EFO:0000384 |
| rheumatoid arthritis | 2 | MONDO:0008383 | EFO:0000685 |
| cystic fibrosis | 2 | MONDO:0009061 | MONDO:0009061 |
| chronic obstructive pulmonary disease | 1 | MONDO:0005002 | EFO:0000341 |
Clinical trials
Total trials: 13.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE1 | 5 |
| PHASE2 | 4 |
| PHASE2/PHASE3 | 2 |
| PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06508021 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUITING | A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP) |
| NCT02520284 | PHASE2/PHASE3 | TERMINATED | Safety and Efficacy of Andecaliximab (GS-5745) in Adults With Moderately to Severely Active Ulcerative Colitis |
| NCT02545504 | PHASE3 | COMPLETED | Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma |
| NCT07024407 | PHASE1/PHASE2 | RECRUITING | A Study of Andecaliximab in People With Spinal Cord Injury at Risk for Bone Growth Outside of the Normal Skeleton. |
| NCT02405442 | PHASE2 | TERMINATED | Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn’s Disease |
| NCT02759562 | PHASE2 | TERMINATED | Effect of Andecaliximab on FEV1 in Adults With Cystic Fibrosis |
| NCT02862574 | PHASE2 | TERMINATED | Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis |
| NCT02864381 | PHASE2 | COMPLETED | Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma |
| NCT01803282 | PHASE1 | COMPLETED | Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors |
| NCT01831427 | PHASE1 | COMPLETED | Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GS-5745 (Andecaliximab) in Adults With Moderate to Severe Active Ulcerative Colitis |
| NCT02077465 | PHASE1 | COMPLETED | Safety, Tolerability, and Pharmacokinetics of Andecaliximab in Adults With Chronic Obstructive Pulmonary Disease (COPD) |
| NCT02176876 | PHASE1 | COMPLETED | Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Rheumatoid Arthritis |
| NCT02862535 | PHASE1 | TERMINATED | Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
25 molecules share ≥1 primary target. Top 25 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| BUDESONIDE | ChEMBL | Phase 4 (approved) | MMP9 |
| BUSULFAN | ChEMBL | Phase 4 (approved) | MMP9 |
| CHLORHEXIDINE | ChEMBL | Phase 4 (approved) | MMP9 |
| CHLOROXINE | ChEMBL | Phase 4 (approved) | MMP9 |
| DACARBAZINE | ChEMBL | Phase 4 (approved) | MMP9 |
| ECONAZOLE | ChEMBL | Phase 4 (approved) | MMP9 |
| PRAZOSIN | ChEMBL | Phase 4 (approved) | MMP9 |
| SECOBARBITAL | ChEMBL | Phase 4 (approved) | MMP9 |
| ZOLEDRONIC ACID | ChEMBL | Phase 4 (approved) | MMP9 |
| CAFFEIC ACID | ChEMBL | Phase 3 | MMP9 |
| CURCUMIN | ChEMBL | Phase 3 | MMP9 |
| MARIMASTAT | ChEMBL | Phase 3 | MMP9 |
| PRINOMASTAT | ChEMBL | Phase 3 | MMP9 |
| QUERCETIN | ChEMBL | Phase 3 | MMP9 |
| AMINOQUINURIDE | ChEMBL | Phase 2 | MMP9 |
| APRATASTAT | ChEMBL | Phase 2 | MMP9 |
| BATIMASTAT | ChEMBL | Phase 2 | MMP9 |
| CIPEMASTAT | ChEMBL | Phase 2 | MMP9 |
| CTS-1027 | ChEMBL | Phase 2 | MMP9 |
| ILOMASTAT | ChEMBL | Phase 2 | MMP9 |
| LUTEOLIN | ChEMBL | Phase 2 | MMP9 |
| REBIMASTAT | ChEMBL | Phase 2 | MMP9 |
| SOLIMASTAT | ChEMBL | Phase 2 | MMP9 |
| TANOMASTAT | ChEMBL | Phase 2 | MMP9 |
| TOSEDOSTAT | ChEMBL | Phase 2 | MMP9 |
Related Atlas pages
- Genes: MMP9
- Diseases: gastric adenocarcinoma
- Drugs: Budesonide, Busulfan, Chlorhexidine, Chloroxine, Dacarbazine, Econazole, Prazosin, Secobarbital, Zoledronic Acid, Caffeic Acid, Curcumin, Marimastat, Prinomastat, Quercetin